-
Mashup Score: 8
Interim trial results show that the only clinical-stage nondepleting anti-OX40 mAb provided rapid skin sign improvement in atopic dermatitis.
Categories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 5NICE recommends first licenced treatment for AL amyloidosis - 3 month(s) ago
Having been available in Scotland and Northern Ireland since 2022, NICE’s decision for the treatment means it is now accessible on the NHS.
Categories: General Medicine News, Onc News and JournalsTweet-
🚨 NEWS 🚨 @NICEComms recommends daratumumab plus bortezomib, cyclophosphamide, and dexamethasone for the treatment of AL amyloidosis. This combination will now be available for eligible patients in England and Wales through the NHS. Read more: https://t.co/moFLW1jzNy #mmsm… https://t.co/QykDgQvolO https://t.co/6ztfYPYPRK
-
-
Mashup Score: 9First European ustekinumab biosimilar to Stelara approved - 4 month(s) ago
The first biosimilar to Stelara® now has European approval, a biologic with indications across disease areas such as gastroenterology.
Categories: General Medicine News, General HCPsTweet
Exciting news in the world of dermatology! A potential best-in-class antibody is showing remarkable efficacy in treating atopic dermatitis. #Dermatology #SkinHealth https://t.co/2q3uW8GZBk https://t.co/vT8rd7o830